Please login to the form below

Not currently logged in
Email:
Password:

Immunocore names CEO

Eliot Forster is chairman of the MedCity project
Immunocore Eliot Forster

The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO.

Dr Forster will lead the firm, which is focused on the development of biological drugs to treat cancer and viral diseases and has several partnerships in place with major pharma companies including Genentech, GlaxoSmithKline and AstraZeneca.

He joins from his role as CEO of Creablis, a UK biotech with a focus on dermatology and pain management, and he also holds the role of chairman of the UK's MedCity project to grow a life sciences cluster in south east England.

“I am delighted to welcome Eliot Forster to Immunocore, and as a member of the Board,” said Dr Jonathan Knowles, executive chairman of the company. “His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC pipeline."

Dr Forster's experience includes role at the pharma major Pfizer where he served as head of development and operations for its operations in the EU and Pfizer. During this time he helped bring several drugs to markets including Celebrex (celecoxib) and Relpax (eletriptan) and to establish the company in India and China.

13th January 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics